Anika Therapeutics, Inc. (NASDAQ: ANIK) Stock Competitors & Peer Comparison
See ANIK's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ANIK and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ANIK | $21.42 | +6.25% | 286.7M | 43.71 | $0.49 | N/A |
| ABT | $107.81 | -0.14% | 186.5B | 20.69 | $5.21 | +2.31% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $339.03 | +0.47% | 130B | 25.32 | $13.39 | +1.03% |
| MDT | $87.16 | +1.44% | 111.6B | 15.76 | $5.53 | +3.29% |
| BSX | $49.31 | +0.02% | 73.3B | 15.91 | $3.10 | N/A |
| EW | $89.72 | +0.45% | 51.7B | 33.23 | $2.70 | N/A |
| DXCM | $84.75 | +2.08% | 32B | 36.37 | $2.33 | N/A |
| RMD | $211.94 | -5.06% | 30.7B | 19.68 | $10.77 | +1.15% |
| PHG | $26.73 | +1.52% | 26.1B | 15.28 | $1.75 | +3.70% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
ANIK vs ABT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ABT has a market cap of 186.5B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ABT trades at $107.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ABT's P/E ratio is 20.69. In terms of profitability, ANIK's ROE is -0.03%, compared to ABT's ROE of +0.11%. Regarding short-term risk, ANIK is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
ANIK vs BSX-PA Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, ANIK's ROE is -0.03%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, ANIK is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BSX-PA's competition here
Stryker Corporation (NYSE: SYK)
ANIK vs SYK Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SYK has a market cap of 130B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SYK trades at $339.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SYK's P/E ratio is 25.32. In terms of profitability, ANIK's ROE is -0.03%, compared to SYK's ROE of +0.16%. Regarding short-term risk, ANIK is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SYK's competition here
Medtronic plc (NYSE: MDT)
ANIK vs MDT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, MDT has a market cap of 111.6B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while MDT trades at $87.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas MDT's P/E ratio is 15.76. In terms of profitability, ANIK's ROE is -0.03%, compared to MDT's ROE of +0.10%. Regarding short-term risk, ANIK is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check MDT's competition here
Boston Scientific Corporation (NYSE: BSX)
ANIK vs BSX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BSX has a market cap of 73.3B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BSX trades at $49.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BSX's P/E ratio is 15.91. In terms of profitability, ANIK's ROE is -0.03%, compared to BSX's ROE of +0.15%. Regarding short-term risk, ANIK is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
ANIK vs EW Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, EW has a market cap of 51.7B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while EW trades at $89.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas EW's P/E ratio is 33.23. In terms of profitability, ANIK's ROE is -0.03%, compared to EW's ROE of +0.10%. Regarding short-term risk, ANIK is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check EW's competition here
DexCom, Inc. (NASDAQ: DXCM)
ANIK vs DXCM Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, DXCM has a market cap of 32B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while DXCM trades at $84.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas DXCM's P/E ratio is 36.37. In terms of profitability, ANIK's ROE is -0.03%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, ANIK is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check DXCM's competition here
ResMed Inc. (NYSE: RMD)
ANIK vs RMD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, RMD has a market cap of 30.7B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while RMD trades at $211.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas RMD's P/E ratio is 19.68. In terms of profitability, ANIK's ROE is -0.03%, compared to RMD's ROE of +0.24%. Regarding short-term risk, ANIK is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check RMD's competition here
Koninklijke Philips N.V. (NYSE: PHG)
ANIK vs PHG Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, PHG has a market cap of 26.1B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while PHG trades at $26.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas PHG's P/E ratio is 15.28. In terms of profitability, ANIK's ROE is -0.03%, compared to PHG's ROE of +0.10%. Regarding short-term risk, ANIK is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
ANIK vs ZBH Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ZBH has a market cap of 18.7B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ZBH trades at $96.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ZBH's P/E ratio is 11.38. In terms of profitability, ANIK's ROE is -0.03%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, ANIK is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
ANIK vs ABMD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ABMD's P/E ratio is 65.36. In terms of profitability, ANIK's ROE is -0.03%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, ANIK is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ABMD's competition here
Penumbra, Inc. (NYSE: PEN)
ANIK vs PEN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while PEN trades at $324.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas PEN's P/E ratio is 84.77. In terms of profitability, ANIK's ROE is -0.03%, compared to PEN's ROE of +0.11%. Regarding short-term risk, ANIK is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check PEN's competition here
Smith & Nephew plc (NYSE: SNN)
ANIK vs SNN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SNN has a market cap of 12.6B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SNN trades at $30.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SNN's P/E ratio is 14.16. In terms of profitability, ANIK's ROE is -0.03%, compared to SNN's ROE of +0.12%. Regarding short-term risk, ANIK is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SNN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
ANIK vs SWAV Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SWAV's P/E ratio is 78.76. In terms of profitability, ANIK's ROE is -0.03%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, ANIK is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
ANIK vs ALGN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ALGN trades at $173.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ALGN's P/E ratio is 15.83. In terms of profitability, ANIK's ROE is -0.03%, compared to ALGN's ROE of +0.14%. Regarding short-term risk, ANIK is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
ANIK vs GMED Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, GMED has a market cap of 11.1B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while GMED trades at $82.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas GMED's P/E ratio is 18.56. In terms of profitability, ANIK's ROE is -0.03%, compared to GMED's ROE of +0.12%. Regarding short-term risk, ANIK is less volatile compared to GMED. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
ANIK vs GKOS Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while GKOS trades at $180.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas GKOS's P/E ratio is -209.45. In terms of profitability, ANIK's ROE is -0.03%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, ANIK is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
ANIK vs PODD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, PODD has a market cap of 9.8B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while PODD trades at $141.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas PODD's P/E ratio is 24.05. In terms of profitability, ANIK's ROE is -0.03%, compared to PODD's ROE of +0.27%. Regarding short-term risk, ANIK is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
ANIK vs BIO-B Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BIO-B has a market cap of 9.5B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BIO-B trades at $349.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BIO-B's P/E ratio is 103.54. In terms of profitability, ANIK's ROE is -0.03%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, ANIK is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BIO-B's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
ANIK vs BIO Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BIO has a market cap of 9.5B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BIO trades at $352.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BIO's P/E ratio is 38.00. In terms of profitability, ANIK's ROE is -0.03%, compared to BIO's ROE of +0.03%. Regarding short-term risk, ANIK is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BIO's competition here
Masimo Corporation (NASDAQ: MASI)
ANIK vs MASI Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas MASI's P/E ratio is 44.43. In terms of profitability, ANIK's ROE is -0.03%, compared to MASI's ROE of +0.09%. Regarding short-term risk, ANIK is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKR)
ANIK vs BRKR Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BRKR has a market cap of 8.1B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BRKR trades at $53.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BRKR's P/E ratio is 26.84. In terms of profitability, ANIK's ROE is -0.03%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, ANIK is more volatile compared to BRKR. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BRKR's competition here
Inari Medical, Inc. (NASDAQ: NARI)
ANIK vs NARI Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas NARI's P/E ratio is -59.24. In terms of profitability, ANIK's ROE is -0.03%, compared to NARI's ROE of -0.00%. Regarding short-term risk, ANIK is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
ANIK vs ITGR Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ITGR trades at $125.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ITGR's P/E ratio is 19.72. In terms of profitability, ANIK's ROE is -0.03%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, ANIK is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
ANIK vs IRTC Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, IRTC has a market cap of 4.2B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while IRTC trades at $127.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas IRTC's P/E ratio is -199.75. In terms of profitability, ANIK's ROE is -0.03%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, ANIK is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check IRTC's competition here
LivaNova PLC (NASDAQ: LIVN)
ANIK vs LIVN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while LIVN trades at $76.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas LIVN's P/E ratio is 18.10. In terms of profitability, ANIK's ROE is -0.03%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, ANIK is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check LIVN's competition here
Haemonetics Corporation (NYSE: HAE)
ANIK vs HAE Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, HAE has a market cap of 4B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while HAE trades at $87.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas HAE's P/E ratio is 17.54. In terms of profitability, ANIK's ROE is -0.03%, compared to HAE's ROE of +0.11%. Regarding short-term risk, ANIK is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check HAE's competition here
Axonics, Inc. (NASDAQ: AXNX)
ANIK vs AXNX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas AXNX's P/E ratio is -709.80. In terms of profitability, ANIK's ROE is -0.03%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, ANIK is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check AXNX's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
ANIK vs TMDX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while TMDX trades at $83.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas TMDX's P/E ratio is 42.58. In terms of profitability, ANIK's ROE is -0.03%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, ANIK is more volatile compared to TMDX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check TMDX's competition here
AxoGen, Inc. (NASDAQ: AXGN)
ANIK vs AXGN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, AXGN has a market cap of 2.5B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while AXGN trades at $46.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas AXGN's P/E ratio is 122.18. In terms of profitability, ANIK's ROE is -0.03%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, ANIK is more volatile compared to AXGN. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check AXGN's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
ANIK vs UFPT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while UFPT trades at $314.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas UFPT's P/E ratio is 32.07. In terms of profitability, ANIK's ROE is -0.03%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, ANIK is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check UFPT's competition here
Butterfly Network, Inc. (NYSE: BFLY)
ANIK vs BFLY Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BFLY has a market cap of 2.3B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BFLY trades at $8.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BFLY's P/E ratio is -36.77. In terms of profitability, ANIK's ROE is -0.03%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, ANIK is more volatile compared to BFLY. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BFLY's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
ANIK vs ESTA Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ESTA trades at $77.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ESTA's P/E ratio is -61.44. In terms of profitability, ANIK's ROE is -0.03%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, ANIK is more volatile compared to ESTA. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
ANIK vs NUVA Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas NUVA's P/E ratio is 75.00. In terms of profitability, ANIK's ROE is -0.03%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, ANIK is more volatile compared to NUVA. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check NUVA's competition here
Novocure Ltd (NASDAQ: NVCR)
ANIK vs NVCR Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, NVCR has a market cap of 1.9B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while NVCR trades at $16.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas NVCR's P/E ratio is -10.71. In terms of profitability, ANIK's ROE is -0.03%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, ANIK is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check NVCR's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
ANIK vs INSP Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while INSP trades at $60.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas INSP's P/E ratio is 26.51. In terms of profitability, ANIK's ROE is -0.03%, compared to INSP's ROE of +0.18%. Regarding short-term risk, ANIK is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check INSP's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
ANIK vs TNDM Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, TNDM has a market cap of 1.5B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while TNDM trades at $22.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas TNDM's P/E ratio is -20.35. In terms of profitability, ANIK's ROE is -0.03%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, ANIK is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check TNDM's competition here
Enovis Corporation (NYSE: ENOV)
ANIK vs ENOV Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ENOV has a market cap of 1.5B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ENOV trades at $26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ENOV's P/E ratio is 7.62. In terms of profitability, ANIK's ROE is -0.03%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, ANIK is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check ENOV's competition here
CONMED Corporation (NYSE: CNMD)
ANIK vs CNMD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CNMD trades at $49.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CNMD's P/E ratio is 10.78. In terms of profitability, ANIK's ROE is -0.03%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, ANIK is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CNMD's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
ANIK vs ATEC Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ATEC has a market cap of 1.4B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ATEC trades at $9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ATEC's P/E ratio is -155.17. In terms of profitability, ANIK's ROE is -0.03%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, ANIK is more volatile compared to ATEC. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ATEC's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
ANIK vs IART Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while IART trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas IART's P/E ratio is 7.31. In terms of profitability, ANIK's ROE is -0.03%, compared to IART's ROE of -0.01%. Regarding short-term risk, ANIK is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check IART's competition here
Artivion, Inc. (NYSE: AORT)
ANIK vs AORT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, AORT has a market cap of 1.3B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while AORT trades at $27.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas AORT's P/E ratio is 45.28. In terms of profitability, ANIK's ROE is -0.03%, compared to AORT's ROE of -0.01%. Regarding short-term risk, ANIK is more volatile compared to AORT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check AORT's competition here
Heska Corporation (NASDAQ: HSKA)
ANIK vs HSKA Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas HSKA's P/E ratio is -62.49. In terms of profitability, ANIK's ROE is -0.03%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, ANIK is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check HSKA's competition here
IRadimed Corporation (NASDAQ: IRMD)
ANIK vs IRMD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while IRMD trades at $92.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas IRMD's P/E ratio is 46.48. In terms of profitability, ANIK's ROE is -0.03%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, ANIK is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check IRMD's competition here
Avanos Medical, Inc. (NYSE: AVNS)
ANIK vs AVNS Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas AVNS's P/E ratio is 27.77. In terms of profitability, ANIK's ROE is -0.03%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, ANIK is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check AVNS's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
ANIK vs PRCT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, PRCT has a market cap of 1.2B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while PRCT trades at $20.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas PRCT's P/E ratio is -10.52. In terms of profitability, ANIK's ROE is -0.03%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, ANIK is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check PRCT's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
ANIK vs SILK Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SILK's P/E ratio is -18.96. In terms of profitability, ANIK's ROE is -0.03%, compared to SILK's ROE of -0.35%. Regarding short-term risk, ANIK is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SILK's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
ANIK vs LMRI Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while LMRI trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas LMRI's P/E ratio is -22.53. In terms of profitability, ANIK's ROE is -0.03%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, ANIK is more volatile compared to LMRI. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check LMRI's competition here
Paragon 28, Inc. (NYSE: FNA)
ANIK vs FNA Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas FNA's P/E ratio is -19.83. In terms of profitability, ANIK's ROE is -0.03%, compared to FNA's ROE of -0.35%. Regarding short-term risk, ANIK is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check FNA's competition here
Bioventus Inc. (NASDAQ: BVS)
ANIK vs BVS Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BVS has a market cap of 956.9M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BVS trades at $14.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BVS's P/E ratio is 18.59. In terms of profitability, ANIK's ROE is -0.03%, compared to BVS's ROE of +0.28%. Regarding short-term risk, ANIK is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BVS's competition here
InMode Ltd. (NASDAQ: INMD)
ANIK vs INMD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, INMD has a market cap of 880M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while INMD trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas INMD's P/E ratio is 10.63. In terms of profitability, ANIK's ROE is -0.03%, compared to INMD's ROE of +0.13%. Regarding short-term risk, ANIK is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check INMD's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
ANIK vs AVR Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, AVR has a market cap of 866.3M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while AVR trades at $8.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas AVR's P/E ratio is -4.00. In terms of profitability, ANIK's ROE is -0.03%, compared to AVR's ROE of -1.24%. Regarding short-term risk, ANIK is more volatile compared to AVR. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check AVR's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
ANIK vs CSII Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CSII's P/E ratio is -20.83. In terms of profitability, ANIK's ROE is -0.03%, compared to CSII's ROE of -0.14%. Regarding short-term risk, ANIK is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CSII's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
ANIK vs SIBN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SIBN has a market cap of 825.3M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SIBN trades at $18.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SIBN's P/E ratio is -54.74. In terms of profitability, ANIK's ROE is -0.03%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, ANIK is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SIBN's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
ANIK vs AHCO Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, AHCO has a market cap of 774.1M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while AHCO trades at $5.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas AHCO's P/E ratio is 11.61. In terms of profitability, ANIK's ROE is -0.03%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, ANIK is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check AHCO's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
ANIK vs SSII Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SSII has a market cap of 754.5M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SSII trades at $3.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SSII's P/E ratio is -73.53. In terms of profitability, ANIK's ROE is -0.03%, compared to SSII's ROE of -0.23%. Regarding short-term risk, ANIK is more volatile compared to SSII. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SSII's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
ANIK vs BBNX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BBNX has a market cap of 715.3M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BBNX trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BBNX's P/E ratio is -10.53. In terms of profitability, ANIK's ROE is -0.03%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, ANIK is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check BBNX's competition here
CeriBell, Inc. (NASDAQ: CBLL)
ANIK vs CBLL Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CBLL has a market cap of 713.7M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CBLL trades at $18.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CBLL's P/E ratio is -11.54. In terms of profitability, ANIK's ROE is -0.03%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, ANIK is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CBLL's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
ANIK vs TCMD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, TCMD has a market cap of 665.4M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while TCMD trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas TCMD's P/E ratio is 33.52. In terms of profitability, ANIK's ROE is -0.03%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, ANIK is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check TCMD's competition here
Surmodics, Inc. (NASDAQ: SRDX)
ANIK vs SRDX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SRDX's P/E ratio is -34.66. In terms of profitability, ANIK's ROE is -0.03%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, ANIK is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SRDX's competition here
BrainsWay Ltd. (NASDAQ: BWAY)
ANIK vs BWAY Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BWAY has a market cap of 608M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BWAY trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BWAY's P/E ratio is 39.38. In terms of profitability, ANIK's ROE is -0.03%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, ANIK is more volatile compared to BWAY. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check BWAY's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
ANIK vs KIDS Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, KIDS has a market cap of 584.8M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while KIDS trades at $22.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas KIDS's P/E ratio is -19.30. In terms of profitability, ANIK's ROE is -0.03%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, ANIK is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check KIDS's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
ANIK vs APEN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas APEN's P/E ratio is -9.43. In terms of profitability, ANIK's ROE is -0.03%, compared to APEN's ROE of -0.85%. Regarding short-term risk, ANIK is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check APEN's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
ANIK vs CTKB Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CTKB has a market cap of 542.4M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CTKB trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CTKB's P/E ratio is -22.25. In terms of profitability, ANIK's ROE is -0.03%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, ANIK is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CTKB's competition here
ZimVie Inc. (NASDAQ: ZIMV)
ANIK vs ZIMV Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, ANIK's ROE is -0.03%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, ANIK is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ZIMV's competition here
Varex Imaging Corporation (NASDAQ: VREX)
ANIK vs VREX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, VREX has a market cap of 522.5M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while VREX trades at $12.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas VREX's P/E ratio is 13.06. In terms of profitability, ANIK's ROE is -0.03%, compared to VREX's ROE of -0.18%. Regarding short-term risk, ANIK is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check VREX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
ANIK vs DCTH Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, DCTH has a market cap of 521.6M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while DCTH trades at $15.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas DCTH's P/E ratio is 1511.00. In terms of profitability, ANIK's ROE is -0.03%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, ANIK is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check DCTH's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
ANIK vs NPCE Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, NPCE has a market cap of 505.6M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while NPCE trades at $14.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas NPCE's P/E ratio is -25.57. In terms of profitability, ANIK's ROE is -0.03%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, ANIK is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check NPCE's competition here
Cerus Corporation (NASDAQ: CERS)
ANIK vs CERS Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CERS has a market cap of 473.6M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CERS trades at $2.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CERS's P/E ratio is -46.91. In terms of profitability, ANIK's ROE is -0.03%, compared to CERS's ROE of -0.10%. Regarding short-term risk, ANIK is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CERS's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
ANIK vs CLPT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CLPT has a market cap of 426.2M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CLPT trades at $14.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CLPT's P/E ratio is -12.04. In terms of profitability, ANIK's ROE is -0.03%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, ANIK is more volatile compared to CLPT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CLPT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
ANIK vs OFIX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, OFIX has a market cap of 415.5M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while OFIX trades at $10.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas OFIX's P/E ratio is -13.43. In terms of profitability, ANIK's ROE is -0.03%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, ANIK is more volatile compared to OFIX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check OFIX's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
ANIK vs SGHT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SGHT has a market cap of 406.4M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SGHT trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SGHT's P/E ratio is -13.34. In terms of profitability, ANIK's ROE is -0.03%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, ANIK is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check SGHT's competition here
Carlsmed, Inc. (NASDAQ: CARL)
ANIK vs CARL Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CARL has a market cap of 375.7M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CARL trades at $13.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CARL's P/E ratio is -9.66. In terms of profitability, ANIK's ROE is -0.03%, compared to CARL's ROE of -0.38%. Regarding short-term risk, ANIK is more volatile compared to CARL. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CARL's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
ANIK vs PACB Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, PACB has a market cap of 368.1M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while PACB trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas PACB's P/E ratio is -2.89. In terms of profitability, ANIK's ROE is -0.03%, compared to PACB's ROE of -49.62%. Regarding short-term risk, ANIK is more volatile compared to PACB. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check PACB's competition here
CapsoVision, Inc. (NASDAQ: CV)
ANIK vs CV Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CV has a market cap of 354.7M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CV trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CV's P/E ratio is -2.84. In terms of profitability, ANIK's ROE is -0.03%, compared to CV's ROE of +1.27%. Regarding short-term risk, ANIK is more volatile compared to CV. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CV's competition here
Picard Medical, Inc. (AMEX: PMI)
ANIK vs PMI Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, PMI has a market cap of 349.2M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while PMI trades at $3.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas PMI's P/E ratio is -2.83. In terms of profitability, ANIK's ROE is -0.03%, compared to PMI's ROE of +4.99%. Regarding short-term risk, ANIK is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check PMI's competition here
Electromed, Inc. (AMEX: ELMD)
ANIK vs ELMD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ELMD has a market cap of 348.5M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ELMD trades at $42.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ELMD's P/E ratio is 35.97. In terms of profitability, ANIK's ROE is -0.03%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, ANIK is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ELMD's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
ANIK vs CATX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, CATX has a market cap of 342.1M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while CATX trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas CATX's P/E ratio is -2.13. In terms of profitability, ANIK's ROE is -0.03%, compared to CATX's ROE of -0.42%. Regarding short-term risk, ANIK is more volatile compared to CATX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check CATX's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
ANIK vs SMLR Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SMLR's P/E ratio is 3.92. In terms of profitability, ANIK's ROE is -0.03%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, ANIK is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check SMLR's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
ANIK vs TMCI Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, TMCI has a market cap of 308.8M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while TMCI trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas TMCI's P/E ratio is -5.06. In terms of profitability, ANIK's ROE is -0.03%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, ANIK is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check TMCI's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
ANIK vs SENS Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, SENS has a market cap of 293.4M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while SENS trades at $7.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas SENS's P/E ratio is -3.51. In terms of profitability, ANIK's ROE is -0.03%, compared to SENS's ROE of -1.66%. Regarding short-term risk, ANIK is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check SENS's competition here
Profound Medical Corp. (NASDAQ: PROF)
ANIK vs PROF Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, PROF has a market cap of 269.3M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while PROF trades at $7.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas PROF's P/E ratio is -5.98. In terms of profitability, ANIK's ROE is -0.03%, compared to PROF's ROE of -0.56%. Regarding short-term risk, ANIK is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
ANIK vs RXST Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, RXST has a market cap of 259.1M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while RXST trades at $6.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas RXST's P/E ratio is -6.73. In terms of profitability, ANIK's ROE is -0.03%, compared to RXST's ROE of -0.17%. Regarding short-term risk, ANIK is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check RXST's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
ANIK vs MGRM Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas MGRM's P/E ratio is -12.00. In terms of profitability, ANIK's ROE is -0.03%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, ANIK is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check MGRM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
ANIK vs FOCL Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, FOCL has a market cap of 233.1M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while FOCL trades at $6.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas FOCL's P/E ratio is -8.00. In terms of profitability, ANIK's ROE is -0.03%, compared to FOCL's ROE of -1.38%. Regarding short-term risk, ANIK is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check FOCL's competition here
Nevro Corp. (NYSE: NVRO)
ANIK vs NVRO Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas NVRO's P/E ratio is -1.91. In terms of profitability, ANIK's ROE is -0.03%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, ANIK is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
ANIK vs TLSI Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, TLSI has a market cap of 212.7M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while TLSI trades at $5.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas TLSI's P/E ratio is -3.34. In terms of profitability, ANIK's ROE is -0.03%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, ANIK is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check TLSI's competition here
Avita Medical Inc. (NASDAQ: RCEL)
ANIK vs RCEL Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, RCEL has a market cap of 193M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while RCEL trades at $7.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas RCEL's P/E ratio is -4.95. In terms of profitability, ANIK's ROE is -0.03%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, ANIK is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check RCEL's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
ANIK vs BSGM Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas BSGM's P/E ratio is -5.81. In terms of profitability, ANIK's ROE is -0.03%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, ANIK is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check BSGM's competition here
Quanterix Corporation (NASDAQ: QTRX)
ANIK vs QTRX Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, QTRX has a market cap of 189.8M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while QTRX trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas QTRX's P/E ratio is -2.52. In terms of profitability, ANIK's ROE is -0.03%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, ANIK is more volatile compared to QTRX. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check QTRX's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
ANIK vs MDGS Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas MDGS's P/E ratio is -0.27. In terms of profitability, ANIK's ROE is -0.03%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, ANIK is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check MDGS's competition here
Neuronetics, Inc. (NASDAQ: STIM)
ANIK vs STIM Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, STIM has a market cap of 165.6M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while STIM trades at $2.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas STIM's P/E ratio is -4.41. In terms of profitability, ANIK's ROE is -0.03%, compared to STIM's ROE of -1.65%. Regarding short-term risk, ANIK is more volatile compared to STIM. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check STIM's competition here
Inogen, Inc. (NASDAQ: INGN)
ANIK vs INGN Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, INGN has a market cap of 163.8M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while INGN trades at $6.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas INGN's P/E ratio is -6.65. In terms of profitability, ANIK's ROE is -0.03%, compared to INGN's ROE of -0.13%. Regarding short-term risk, ANIK is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for ANIK.Check INGN's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
ANIK vs QIPT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas QIPT's P/E ratio is -15.87. In terms of profitability, ANIK's ROE is -0.03%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, ANIK is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check QIPT's competition here
iCAD, Inc. (NASDAQ: ICAD)
ANIK vs ICAD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas ICAD's P/E ratio is -20.37. In terms of profitability, ANIK's ROE is -0.03%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, ANIK is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check ICAD's competition here
Owlet, Inc. (NYSE: OWLT)
ANIK vs OWLT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, OWLT has a market cap of 99.9M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while OWLT trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas OWLT's P/E ratio is -39.43. In terms of profitability, ANIK's ROE is -0.03%, compared to OWLT's ROE of +11.36%. Regarding short-term risk, ANIK is more volatile compared to OWLT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check OWLT's competition here
Lucid Diagnostics Inc. (NASDAQ: LUCD)
ANIK vs LUCD Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, LUCD has a market cap of 98.9M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while LUCD trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas LUCD's P/E ratio is -2.61. In terms of profitability, ANIK's ROE is -0.03%, compared to LUCD's ROE of -3.70%. Regarding short-term risk, ANIK is more volatile compared to LUCD. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check LUCD's competition here
Solana Company (NASDAQ: HSDT)
ANIK vs HSDT Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, HSDT has a market cap of 98.7M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while HSDT trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas HSDT's P/E ratio is -0.02. In terms of profitability, ANIK's ROE is -0.03%, compared to HSDT's ROE of -1.55%. Regarding short-term risk, ANIK is more volatile compared to HSDT. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check HSDT's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
ANIK vs HJLI Comparison August 2026
Anika Therapeutics, Inc. (NASDAQ: ANIK) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ANIK stands at 286.7M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, ANIK is priced at $21.42 on the NASDAQ, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ANIK currently has a P/E ratio of 43.71, whereas HJLI's P/E ratio is N/A. In terms of profitability, ANIK's ROE is -0.03%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, ANIK is more volatile compared to HJLI. This indicates higher risk in terms of short-term price fluctuations for ANIK.Check HJLI's competition here